Liang Cheng/X
Mar 20, 2025, 15:51
Liang Cheng: Current androgen receptor antagonists under investigation for resistant prostate cancer
Liang Cheng, Vice Chair for Translational Research at Warren Alpert Medical School of Brown University, shared his recent article on X:
“I am delighted to share this NEWEST article from Expert Review of Anticancer Therapy!
Congratulations to Professor Francesco Massari, Linda Danielli, and the Team.”
Authors: Linda Danielli, et al.
Summary of the article:
- Prostate cancer progression is largely driven by androgen receptor (AR) signaling, making androgen receptor signaling inhibitors (ARSIs) a cornerstone of treatment for castration-resistant prostate cancer (CRPC). However, resistance mechanisms necessitate novel therapeutic approaches.
- Recent advancements focus on combination therapies, including ARSIs with PARP inhibitors (PROpel, MAGNITUDE, TALAPRO-2 trials), radioligand therapies (radium-223, lutetium-177), and novel agents targeting DNA repair and alternative signaling pathways.
- Future directions emphasize biomarker-driven treatment selection, optimized therapy sequencing, and innovative strategies to overcome resistance, aiming to enhance clinical outcomes and personalize care in CRPC management.
More posts featuring Liang Cheng.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 13, 2025, 05:56
Apr 13, 2025, 05:55
Apr 13, 2025, 05:10
Apr 13, 2025, 05:05
Apr 13, 2025, 04:50
Apr 13, 2025, 04:21